Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 17/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 17/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 17/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 17/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872754 | 0.90 | OPRM1 (0.52) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4863798 | 0.81 | OPRL1 (0.44) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4871392 | 0.80 | OPRL1 (0.41) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4867904 | 0.79 | OPRL1 (0.46) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4864139 | 0.79 | OPRL1 (0.65) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL4869997 | 0.77 | OPRL1 (0.40) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4867474 | 0.77 | USP2 (0.43) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL4864454 | 0.75 | OPRL1 (0.43) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4870342 | 0.75 | SIGMAR1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4861154 | 0.74 | CYP3A4 (0.46) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | claimed |
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SULT1E1, TST, TMT1A | OPRM1 3149/4885OPRD1 1975/4885OPRK1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.